Although I don’t hold but watch with interest
Can any one tell me what is so different between Bubs formulation and A2Ms that would need FDA to defer ?
I’m sure the safety aspects have been well proven in the market place
Ann: Deferral of FDA consideration of enforcement discretion, page-19
-
- There are more pages in this discussion • 123 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.14 |
Change
-0.220(3.46%) |
Mkt cap ! $4.445B | |||
| Open | High | Low | Value | Volume |
| $6.30 | $6.33 | $6.12 | $14.77M | 2.391M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 17044 | $6.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.17 | 3624 | 2 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| A2M (ASX) Chart |